|
|
|
|
LEADER |
03417nam a2200289 u 4500 |
001 |
EB001839403 |
003 |
EBX01000000000000001003392 |
005 |
00000000000000.0 |
007 |
tu||||||||||||||||||||| |
008 |
180702 r ||| eng |
245 |
0 |
0 |
|a 5-Fluorouracil 0.5% and salicylic acid 10.0% (Actikerall)
|h Elektronische Ressource
|
260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2017, 2017
|
300 |
|
|
|a 1 online resource
|b illustrations
|
505 |
0 |
|
|a Includes bibliographical references
|
653 |
|
|
|a Fluorouracil / administration & dosage
|
653 |
|
|
|a Salicylic Acid / administration & dosage
|
653 |
|
|
|a Keratosis, Actinic / drug therapy
|
653 |
|
|
|a Treatment Outcome
|
710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
490 |
0 |
|
|a Common drug review
|
856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK476506
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
082 |
0 |
|
|a 610
|
520 |
|
|
|a In Canada, 74,100 new cases of non-melanoma skin cancers (NMSCs) and 270 deaths due to these cancers were predicted for 2011.2 AK typically manifests as 2 mm to 6 mm scaly macules, papules, or plaques that are skin to reddish-brown in colour, and may be flat or thickened (hyperkeratotic).4,5 Patients with AK are usually referred to dermatologists and diagnosis is frequently made on clinical appearance alone.1 A skin biopsy may be required when there is clinical doubt or suspicion of invasive malignancy.1,5 Detectable AK may be associated with a field change where the surrounding skin is also altered and subclinical lesions may be present.2 Patient input to the CADTH Common Drug Review (CDR) suggests that cosmetic issues are a major concern for patients, and this can have a negative impact on self-confidence. The submitted product is a combination of two topical therapies, 5-fluorouracil 0.5% (5-FU) and salicylic acid 10% (SA).
|
520 |
|
|
|a According to the British Association of Dermatologists, 15% to 25% of actinic keratosis (AK) lesions spontaneously resolve during a one-year period.1 However, AK lesions may develop into invasive squamous cell carcinoma (SCC) if left untreated.2 The rate of progression from AK to SCC is unknown. Mathematical models derived from a study predicted that for an individual with an average of 7.7 AKs, the probability of developing an SCC at the same or nearby site within a 10-year period is approximately 10.3 The risk of malignant transformation is higher in patients who are immunocompromised.
|
520 |
|
|
|a 5-FU is an antimetabolite that is already approved as monotherapy for treatment of AK, although at a concentration of 5%. SA is a keratolytic, and the theory behind its use is to improve penetration of the combination in hyperkeratotic AK. The 5-FU/SA combination under review is administered once daily to affected lesions, until lesions have cleared or for a maximum of 12 weeks. It is indicated for the management of grade I/II hyperkeratotic AK. The objective of this report was to perform a systematic review of the beneficial and harmful effects of 5-FU (0.5%) combined with SA 10% applied topically once daily for the topical treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (grade I/II) of the face, forehead, and balding scalp in immunocompetent adult patients
|